Cancer stem cells of sarcoma

Role of Cancer Stem Cells in Cancer Biology and Therapy

Volumn , Issue , 2016, Pages 23-78

  Fujiwara, Tomohiro ^a,b,c   Kawai, Akira ^b   Yoshida, Akihiko ^b   Ozaki, Toshifumi ^c   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907371664     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (216)

1. Adhikari, A.S., N. Agarwal, B.M. Wood, C. Porretta, B. Ruiz, R.R. Pochampally, and T. Iwakuma. 2010. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70: 4602-4612.
2. Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
3. Alison, M.R., S.M. Lim, and L.J. Nicholson. 2010. Cancer stem cells: problems for therapy? J Pathol 27.
4. Altieri, D.C. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
5. Ambroziak, W., G. Izaguirre, and R. 1999. Pietruszko. Metabolism of retinaldehyde and other aldehydes in soluble extracts of human liver and kidney. J Biol Chem 274: 33366-33373.
6. Aogi, K., A. Woodman, V. Urquidi, D.C. Mangham, D.T. arin, and S. Goodison. 2000. Telomerase activity in soft-tissue and bone sarcomas. Clin Cancer Res. 6: 4776-4781.
7. Aoyama, T., T. Okamoto, S. Nagayama, K. Nishijo, T. Ishibe, K. Yasura, T. Nakayama, T. Nakamura, and J. Toguchida. 2004. Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3. J Biol Chem 279: 28789-28797.
8. Armstrong, L., M. Stojkovic, I. Dimmick, S. Ahmad, P. Stojkovic, N. Hole, and M. Lako. 2004. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22: 1142-1151.
9. Artavanis-Tsakonas, S., M.D. Rand, and R.J. Lake. 1999. Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
10. Aryee, D.N., S. Niedan, M. Kauer, R. Schwentner, I.M. Bennani-Baiti, J. Ban, K. Muehlbacher, M. Kreppel, R.L. Walker, P. Meltzer, C. Poremba, R. Kofler, and H. Kovar. 2010. Hypoxia modulates EWS-FLI1 transcriptional signatureand enhances the malignant properties of Ewing's sarcoma cells in vitro, Cancer Res 70: 4015-4023.
11. Avilion, A.A., S.K. Nicolis, L.H. Pevny, L. Perez, N. Vivian, and R. Lovell-Badge. 2003. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17: 126-140.
12. Awad, O., J.T. Yustein, P. Shah, N. Gul, V. Katuri, A. O'Neill, Y. Kong, M.L. Brown, J.A. Toretsky, and D.M. Loeb. 2010. High aldh activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to ews-fli1 inhibition. PLoS One 5: e13943.
13. Bacci, G., S. Ferrari, F. Bertoni, P. Ruggieri, P. Picci, A. Longhi, R. Casadei, N. Fabbri, C. Forni, M. Versari, and M. Campanacci. 2000. Long-term outcome for patientswith nonmetastatic osteosarcoma of the extremity treated at thelstituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18: 4016-4027.
14. Baksh, D., and R.S. Tuan. 2007. Canonical and non-canonical Wnts differentially affect the developmentpotential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 212: 817-826.
15. Banas, A., T. Teratani, Y. Yamamoto, M. Tokuhara, F. Takeshita, M. Osaki, M. Kawamata, T. Kato, H. Okochi, and T. Ochiya. 2008. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 26: 2705-2712.
16. Barker, N., M. Huch, P. Kujala, M. van de Wetering, H.J. Snippert, J.H. van Es, T. Sato, D. E. Stange, H. Begthel, M. van den Born, E. Danenberg, S. van den Brink, J. Korving, A. Abo, PJ. Peters, N. Wright, R. Poulsom, and H. Clevers. 2010. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cel! 6: 25-36.
17. Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
18. Basu-Roy, U., E. Seo, L. Ramanathapuram, T.B. Rapp, J.A. Perry, S.H. Orkin, A. Mansukhani, and C. Basilico. 2011. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene. doi: 10.1038/onc.2011.405
19. Bennani-Baiti, I.M., D.N. Aryee, J. Ban, I. Machado, M. Kauer, K. Mühlbacher, G. Amann, A. Llombart-Bosch, and H. Kovar. 2011. Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. J Pathol 225: 353-363.
20. Bielack, S., B. Kempf-Bielack, D. Schwenzer, T. Birkfellner, G. Delling, V. Ewerbeck, G.U. Exner, N. Fuchs, U. Göbel, N. Graf, U. Heise, K. Helmke, A.R. von Hochstetter, H. Jürgens, R. Maas, N. Münchow, M. Salzer-Kuntschik, J. Treuner, U. Veltmann, M. Werner, W. Winkelmann, A. Zoubek, and R. Kotz. 1999. Neoadjuvanttherapy for localized osteosarcoma of extremities: results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 211: 260-270.
21. Bolós, V., J. Grego-Bessa, and J.L. de la Pompa. 2007. Notch signaling in development and cancer. Endocr Rev 28: 339-363.
22. Brady, M.S., G. Perino, G. Tallini, P. Russo, and J.M. Woodruff. 1996. Malignant mesenchymoma. Cancer 77: 467-473.
23. Carpentino, J.E., M.J. Hynes, H.D. Appelman, T. Zheng, D.A. Steindler, E.W. Scott, and E. H. Huang. 2009. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 69: 8208-8215.
24. Catton, C., B. O'Sullivan, R. Bell, N. Laperriere, B. Cummings, V. Fornasier, and J. Wunder. 1996. Chordoma: Long-term follow-up after radical photonirradiation. Radiother Oncol 41: 67-72.
25. Cha, E.J. 2011. Dedifferentiated liposarcoma of the small bowel mesentery presenting as a submucosal mass. World J Gastrointest Oncol 3: 116-118.
26. Chambers, P.W., and C.P. Schwinn. 1979. Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol 72: 765-776.
27. Charafe-Jauffret, E., C. Ginestier, F. Iovino, C. Tarpin, M. Diebel, B. Esterni, G. Houvenaeghel, J.M. Extra, F. Bertucci, J. Jacquemier, L. Xerri, G. Dontu, G. Stassi, Y. Xiao, S.H. Barsky, D. Birnbaum, P. Viens, and M.S. Wicha. 2010. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 16: 45-55.
28. Chiba, T., S. Miyagi, A. Saraya, R. Aoki, A. Seki, Y. Morita, Y. Yonemitsu, O. Yokosuka, H. Taniguchi, H. Nakauchi, and A. Iwama. 2008. The polycomb gene product bmi1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 68: 7742-7749.
29. Cheng, J.X., B.L. Liu, and X. Zhang. 2009. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 35: 403-408.
30. Chiyomaru, T., H. Enokida, S. Tatarano, K. Kawahara, Y. Uchida, K. Nishiyama, L. Fujimura, N. Kikkawa, N. Seki, and M. Nakagawa. 2010. miR-145 and miR-133a function as tumor suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891.
31. Chugh, R., H. Tawbi, D.R. Lucas, J.S. Biermann, S.M. Schuetze, and L.H. Baker. 2007. Chordoma: the nonsarcoma primary bone tumor. Oncologist 12: 1344-1350.
32. Clarke, M.F., J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, D.L. Jones, J. Visvader, I. L. Weissman, and G.M. Wahl. 2006. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
33. Clevers, H. 2011. The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
34. Collins, A.T., PA. Berry, C. Hyde, M.J. Stower, and N.J. Maitland. 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
35. Cripe, T.P., P.Y. Wang, P Marcato, Y.Y. Mahller, and P.W. Lee. 2009. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 17: 1677-1682.
36. Croce, C.M. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
37. Dahlin, D.C., and J.W. Beabout. 1971. Dedifferentiation of lowgrade chondrosarcomas. Cancer 28: 461-466.
38. Da Silva Meirelles, L., T.T. Sand, R.J. Harman, D.P. Lennon, and A.I. Caplan. 2009. MSC frequency correlates with blood vessel density in equine adipose tissue. Tissue Eng Part A 15: 221-229.
39. David, E., F. Blanchard, M.F. Heymann, G. De Pinieux, F. Gouin, F. Rédini, and D. Heymann. 2011. The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumor Growth and also a Source of New Therapeutic Targets. Sarcoma 2011: 932451.
40. De Giovanni, C., L. Landuzzi, G. Nicoletti, PL. Lollini, and P Nanni. 2009. Molecularand cellular biology of rhabdomyosarcoma. Future Oncol 5: 1449-1475.
41. De Jong, J., and L.H. Looijenga. 2006. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog 12: 171-203.
42. Di Fiore, R., A. Santulli, R.D. Ferrante, M. Giuliano, A. De Blasio, C. Messina, G. Pirozzi, V. Tirino, G. Tesoriere, and R. Vento. 2009. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 219: 301-313.
43. Ding, Y., E.A. Boguslawski, B.D. Berghuis, J.J. Young, Z. Zhang, K. Hardy, K. Furge, E. Kort, A.E. Frankel, R.V. Hay, J.H. Resau, and N.S. Duesbery. 2008. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7: 648-658.
44. Dorfman, H.D., and B. Czerniak. 1995. Bone cancers. Cancer 75: 203-210.
45. Downing, J.R., A. Khandekar, S.A. Shurtleff, D.R. Head, D.M. Parham, B.L. Webber, A.S. Pappo, M.G. Hulshof, W.P. Conn, and D.N. Shapiro. 1995. Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am J Pathol 146: 626-634.
46. Duester, G., F.A. Mic, and A. Molotkov. 2003. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chem Biol Interact 143-144: 201-210.
47. Eilber, F.C., M.F. Brennan, F.R. Eilber, J.J Eckardt, S.R. Grobmyer, E. Riedel, C. Forscher, R.G. Maki, and S. Singer. 2007. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 246: 105-113.
48. Engin, F., Z. Yao, T. Yang, G. Zhou, T. Bertin, M.M. Jiang, Y. Chen, L. Wang, H. Zheng, R.E. Sutton, B.F. Boyce, and B. Lee. 2008. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 14: 299-305.
49. Entz-Werle, N., L. Marcellin, M.P. Gaub, E. Guerin, A. Schneider, P. Berard-Marec, C. Kalifa, L. Brugiere, H. Pacquement, C. Schmitt, M.D. Tabone, C. Jeanne-Pasquier, P. Terrier, F. Dijoud, P. Oudet, P. Lutz, and A. Babin-Boilletot. 2005. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 23: 2248-2255.
50. Entz-Werle, N., M.P. Gaub, T. Lavaux, L. Marcellin, N. Metzger, P. Marec-Berard, C. Schmitt, L. Brugiere, C. Kalifa, M.D. Tabone, H. Pacquement, P. Gentet, P. Lutz, P. Oudet, and A. Babin. 2007. KIT gene in pediatric osteosarcomas: could it be a new therapeutic target? Int J Cancer 120: 2510-2516.
51. Esiashvili, N., M. Goodman, and R.B. Marcus Jr. 2008. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430.
52. Esnaola, N.F., B.P. Rubin, E.H. Baldini, N. Vasudevan, G.D. Demetri, C.D. Fletcher, and S. Singer. 2001. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 234: 215-223.
53. Evans, H.L., A.G. Ayala, and M.M. Romsdahl. 1977. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 40: 818-831.
54. Evans, H.L. 1979. Liposarcoma: a study of 55 cases with areassessment of its classification. Am J Surg Pathol 3: 507-523.
55. Farshid, G., M. Pradhan, J. Goldblum, and S.W. Weiss. 2002. Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol 26: 14-24.
56. Ferguson, W., and A. Goorin. 2001. Current treatment of osteosarcoma. Cancer Invest 19: 292-315.
57. Ferraresi, V., C. Nuzzo, C. Zoccali, F. Marandino, A. Vidiri, N. Salducca, M. Zeuli, D. Giannarelli, F. Cognetti, and R. Biagini. 2010. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer 10: 22.
58. Ferrari, A., G. Bisogno, R. Alaggio, G. Cecchetto, P. Collini, A. Rosolen, C. Meazza, P. Indolfi, A. Garaventa, L. De Sio, P. D'Angelo, P. Tamaro, M. Casanova, and M. Carli. 2008. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 44: 1202-1209.
59. Ferrari, S., E. Palmerini, E.L. Staals, M. Mercuri, B. Franco, P. Picci, and G. Bacci. 2009. The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future. Cancer Treat Res 152: 275-287.
60. Fibbe, W.E. 2002. Mesenchymal stem cells. A potential source for skeletal repair. Ann Rheum Dis 61: ii29-31.
61. Fletcher, C.D.M., K.K. Unni, and F. Mertens. 2002. World Health Organisation classification of tumors. Pathology and genetics of tumors of soft tissue and bone. IARC Press, Lyon, France.
62. Fleming, G.F., P.S. Heimann, J.K. Stephens, M.A. Simon, M.K. Ferguson, R.S. Benjamin, and B. L. Samuels. 1993. Dedifferentiated chordoma. Response toaggressive chemotherapy in two cases. Cancer 72: 714-718.
63. Friedenstein, A.J., J.F. Gorskaja, and N.N. Kulagina. 1976. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. ExpHematol 4: 267-274.
64. Fuchs, D., V. Daniel, M. Sadeghi, G. Opelz, and C. Naujokat. 2010. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 394: 1098-1104.
65. Fujii, H., K. Honoki, T. Tsujiuchi, A. Kido, K. Yoshitani, and Y. Takakura. 2009. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34: 1381-1386.
66. Furlong, M.A., T. Mentzel, and J.C. Fanburg-Smith. 2001. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol 14: 595-603.
67. Galli, R., U. Borello, A. Gritti, M.G. Minasi, C. Bjornson, M. Coletta, M. Mora, M.G. De Angelis, R. Fiocco, G. Cossu, and A.L. Vescovi. 2000. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci 3: 986-991.
68. Geller, D.S., and R. Gorlick. 2010. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: 705-718.
69. Gelderblom, H., P.C. Hogendoorn, S.D. Dijkstra, C.S. van Rijswijk, A.D. Krol, A.H. Taminiau, and J.V. Bovée. 2008. The clinical approach towards chondrosarcoma. Oncologist 13: 320-329.
70. Gibbs, C.P., V.G. Kukekov, J.D. Reith, O. Tchigrinova, O.N. Suslov, E.W. Scott, S.C. Ghivizzani, T.N. Ignatova, and D.A. Steindler. 2005. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
71. Gidekel, S., G. Pizov, Y. Bergman, and E. Pikarsky. 2003. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4: 361-370.
72. Goodell, M.A., M. Rosenzweig, H. Kim, D.F. Marks, M. DeMaria, G. Paradis, S.A. Grupp, C.A. Sieff, R.C. Mulligan, and R.P. Johnson. 1997. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3: 1337-1345.
73. Gregory, C.A., H. Singh, A.S. Perry, and D.J. Prockop. 2003. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 278: 28067-28078.
74. Gronthos, S., S.E. Graves, S. Ohta, and PJ. Simmons. 1994. The STRO-1+ fractionof adult human bone marrow contains the osteogenic precursors. Blood 84: 4164-4173.
75. Guo, L., R.C. Zhao, and Y. Wu. 2011. The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp Hematol 39: 608-616.
76. Gupta, P.B., T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, and E.S. Lander. 2009. Identification of selective inhibitors ofcancer stem cells by high-throughput screening. Cell 138: 645-659.
77. Halldorsson, A., S. Brooks, S. Montgomery, and S. Graham. 2009. Lung metastasis 21 years after initial diagnosis of osteosarcoma: a case report. J Med Case Reports 3: 9298.
78. Heddleston, J.M., Z. Li, J.D. Lathia, S. Bao, A.B. Hjelmeland, and J.N. Rich. 2010. Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795.
79. Henriksen, J., M. Stabell, L.A. Meza-Zepeda, S.A. Lauvrak, M. Kassem, and O. Myklebost. 2010. Identification of targetgenes for wild type and truncated HMGA2 in mesenchymal stem-likecells. BMC Cancer 10: 329.
80. Hermann, P.C., S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, M. Guba, C.J. Bruns, and C. Heeschen. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323
81. Hess, D.A., T.E. Meyerrose, L. Wirthlin, T.P. Craft, P.E. Herrbrich, M.H. Creer, and J.A. Nolta. 2004. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104: 1648-1655.
82. Higinbotham, N.L., R.F. Phillips, H.W. Farr, and H.O. Hustu. 1967. Chordoma. Thirty-five year study at Memorial Hospital. Cancer 20: 1841-1850.
83. Hirotsu, M., T. Setoguchi, Y. Matsunoshita, H. Sasaki, H. Nagao, et al. 2009. Tumor formation by single fibroblast growth factor receptor 3-positiverhabdomyosarcoma-initiating cells. Br J Cancer 101: 2030-2037.
84. Honoki, K., H. Fujii, A. Kubo, A. Kido, T. Mori, Y. Tanaka, and T. Tsujiuchi. 2010. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24: 501-505.
85. Honoki, K. 2010. Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 10: 261-270.
86. Huang, X., and J. Saint-Jeannet. 2004. Induction of the neural crest and the opportunities of life on the edge. Developmental Biology 275: 1-11.
87. Huber, M.A., N. Kraut, and H. Beug. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558.
88. Ibrahim, S.F., A.H. Diercks, T.W. Petersen, and G. van den Engh. 2007. Kinetic analyses as a critical parameter in defining the side population (SP) phenotype. Exp Cell Res 313: 1921-1926.
89. Ischenko, I., H. Seeliger, M. Schaffer, K.W. Jauch, and C.J. Bruns. 2008. Cancer stem cells: how can we target them? Curr Med Chem 15: 3171-3184.
90. Iwasaki, H., and T. Suda. 2009. Cancer stem cells and their niche. Cancer Sci 100: 1166-1172.
91. James, G., M. Crocker, A. King, I. Bodi, A. Ibrahim, and B.P. Chitnavis. 2008. Malignant triton tumors of the spine. J Neurosurg Spine 8: 567-573.
92. Jamil, N., S. Howie, and D.M. Salter. 2010. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol 91: 387-393.
93. Jedlicka, P. 2010. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 193: 338-347.
94. Jones, R.L., C. Fisher, O. Al-Muderis, and I.R. Judson. 2005. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41: 2853-2860.
95. Jiang, X., Y. Gwye, D. Russell, C. Cao, D. Douglas, L. Hung, H. Kovar, T.J. Triche, E.R. Lawlor. 2010. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 2610: 116.
96. Katoh, M., C. Shaw, Q. Xu, N. Van Driessche, T. Morio, H. Kuwayama, S. Obara, H. Urushihara, Y. Tanaka, and G. Shaulsky. 2004. An orderly retreat: Dedifferentiation is a regulated process. Proc Natl Acad Sci USA 101: 7005-7010.
97. Kawamoto, E.H., N. Weidner, R.M. Agostini Jr, and R. Jaffe. 1987. Malignant ectomesenchymoma of soft tissue report of two cases and review of the literature. Cancer 59: 1791-1802.
98. Kawai, A., J. Woodruff, J.H. Healey, M.F. Brennan, C.R. Antonescu, and M. Ladanyi. 1998. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338: 153-160.
99. Kelly, S.E., A. Di Benedetto, A. Greco, C.M. Howard, V.E. Sollars, D.A. Primerano, J.V. Valluri, and P.P. Claudio. 2010. Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One 5: e10035.
100. Kim, V.N., J. Han, and M.C. Siomi. 2009. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139.
101. Kosaka, N., H. Iguchi, and T. Ochiya. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092.
102. Kubo, T., T. Sugita, S. Shimose, T. Matsuo, K. Arihiro, and M. Ochi. 2008. Expression of hypoxia-inducible factor-1alpha and its relationship to tumor angiogenesis and cell proliferation in cartilage tumors. J Bone Joint Surg Br 90: 364-370.
103. Kuhn, N.Z., and R.S. Tuan. 2010. Regulation of stemness and stem cell niche ofmesenchymal stem cells: implications in tumorigenesis and metastasis. J Cell Physiol 222: 268-277.
104. Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick. 1994. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645-648.
105. Le Douarin, N.M., G.W. Calloni, and E. Dupin. 2008. The stem cells of the neural crest. Cell Cycle 7: 1013-1019.
106. Lee, A., J.D. Kessler, T.A. Read, C. Kaiser, D. Corbeil, W.B. Huttner, J.E. Johnson, and R. J. Wechsler-Reya. 2005. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8: 723-729.
107. Lehnhardt, M., A. Daigeler, H.H. Homann, V. Schwaiberger, O. Goertz, C. Kuhnen, H.U. Steinau. 2009. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients. Langenbecks Arch Surg 394: 313-320.
108. Levings, P.P., S.V. McGarry, T.P Currie, D.M. Nickerson, S. McClellan, S.C. Ghivizzani, D.A. Steindler, and C.P. Gibbs. 2009. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69: 5648-5655.
109. Li, C., D.G. Heidt, P. Dalerba, C.F. Burant, L. Zhang, V. Adsay, M. Wicha, M.F. Clarke, and D.M. Simeone. 2007. Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
110. Li, J., W. Liu, K. Zhao, Y. Zhang, X. Li, Q. Yang, Z. Li, and J. Li. 2009. Diallyl trisulfide reverses drug resistance and lowers the ratio of CD133+ cells in conjunction with methotrexate in a human osteosarcoma drug-resistant cell subline. Mol Med Report 2: 245-252.
111. Lin, G.L., and K.D. Hankenson. 2011. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 112: 3491-3501.
112. Lindner, N.J., O. Ramm, A. Hillmann, R. Roedl, G. Gosheger, C. Brinkschmidt, H. Juergens, and W. Winkelmann. 1999. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res 358: 83-89.
113. Liu, X., Y. Sun, J. Guo, H. Ma, J. Li, B. Dong, G. Jin, J. Zhang, J. Wu, L. Meng, and C. Shou. 2006. Expression of hiwi gene in human gastric cancer wasassociated with proliferation of cancer cells. Int J Cancer 118: 1922-1929.
114. Longhi, A., C. Errani, M. De Paolis, M. Mercuri, and G. Bacci. 2006. Primary boneosteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436.
115. Maeda, S., H. Shinchi, H. Kurahara, Y. Mataki, K. Maemura, M. Sato, S. Natsugoe, T. Aikou, and S. Takao. 2008. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-c expression in pancreatic cancer. Br J Cancer 98: 1389-1397.
116. Malanchi, I., H. Peinado, D. Kassen, T. Hussenet, D. Metzger, P. Chambon, M. Huber, D. Hohl, A. Cano, W. Birchmeier, and J. Huelsken. 2008. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653.
117. Mankin, H.J., J. Casas-Ganem, J.I. Kim, M.C. Gebhardt, F.J. Hornicek, and E.N. Zeegen. 2004. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res 421: 225-231.
118. Marina, N., M. Gebhardt, L. Teot, and R. Gorlick. 2004. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441.
119. Masui, S., Y. Nakatake, Y. Toyooka, D. Shimosato, R. Yagi, K. Takahashi, H. Okochi, A. Okuda, R. Matoba, A.A. Sharov, M.S. Ko, and H. Niwa. 2007. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635.
120. Matsui, W., C.A. Huff, Q. Wang, M.T. Malehorn, J. Barber, Y. Tanhehco, B.D. Smith, C.I. Civin, and R.J. Jones. 2004. Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
121. Matushansky, I., R.G. Maki, and C. Cordon-Cardo. 2008. A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle 7: 720-724.
122. Matushansky, I., E. Hernando, N.D. Socci, J.E. Mills, T.A. Matos, M.A. Edgar, S. Singer, R.G. Maki, and C. Cordon-Cardo. 2007. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117: 3248-3257.
123. McDowell, H.P. 2003. Update on childhood rhabdomyosarcoma. Arch Dis Child 88: 354-357.
124. Merlino, G., and C. Khanna. 2007. Fishing for the origins of cancer. Genes Dev 21: 1275-1279.
125. Meyers, P.A., R. Gorlick, G. Heller, E. Casper, J. Lane, A.G. Huvos, and J.H. Healey. 1998. Intensification of preoperativechemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16: 2452-2458.
126. Meyers, P.A., C.L. Schwartz, M.D. Krailo, J.H. Healey, M.L. Bernstein, D. Betcher, W.S. Ferguson, M.C. Gebhardt, A.M. Goorin, M. Harris, E. Kleinerman, M.P. Link, H. Nadel, M. Nieder, G.P. Siegal, M.A. Weiner, R.J. Wells, R.B. Womer, and H.E. Grier. 2008. Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26: 633-638.
127. Misra, A., N. Mistry, R. Grimer, and F. Peart. 2009. The management of soft tissue sarcoma. J Plast Reconstr Aesthet Surg 62: 161-174.
128. Mizrak, D., M. Brittan, and M.R. Alison. 2008. CD133: Molecule of the moment. J Pathol 214: 3-9.
129. Mohseny, A.B., K. Szuhai, S. Romeo, E.P. Buddingh, I. Briaire-de Bruijn, D. de Jong, M. van Pel, A.M. Cleton-Jansen, and P.C. Hogendoorn. 2009. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219: 294-305.
130. Monk, M., and C. Holding. 2001. Human embryonic genes re-expressed in cancer cells. Oncogene 20: 8085-8091.
131. Morrison, S.J., P.M. White, C. Zock, and D.J. Anderson. 1999. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 96: 737-749.
132. Murase, M., M. Kano, T. Tsukahara, A. Takahashi, T. Torigoe, S. Kawaguchi, S. Kimura, T. Wada, Y. Uchihashi, T. Kondo, T. Yamashita, and N. Sato. 2009. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 101: 1425-1432.
133. Nagao, H., K. Ijiri, M. Hirotsu, Y. Ishidou, T. Yamamoto, S. Nagano, T. Takizawa, K. Nakashima, S. Komiya, T. Setoguchi. 2011. Role of GLI2 in the growth of human osteosarcoma. J Pathol 224: 169-179.
134. Nagoshi, N., S. Shibata, M. Nakamura, Y. Matsuzaki, Y. Toyama, and H. Okano. 2009. Neural crest-derived stem cells display a wide variety of characteristics. J Cell Biochem 107: 1046-1052.
135. Nagoshi, N., S. Shibata, Y. Kubota, M. Nakamura, Y. Nagai, E. Satoh, S. Morikawa, Y. Okada, Y. Mabuchi, H. Katoh, S. Okada, K. Fukuda, T. Suda, Y. Matsuzaki, Y. Toyama, and H. Okano. 2008. Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad. Cell Stem Cell 2: 392-403.
136. Naka, N., S. Takenaka, N. Araki, T. Miwa, N. Hashimoto, K. Yoshioka, S. Joyama, K. Hamada, Y. Tsukamoto, Y. Tomita, T. Ueda, H. Yoshikawa, and K. Itoh. 2010. Synovial sarcoma is a stem cell malignancy. Stem Cells 28: 1119-1131.
137. Ng, T.L., A.M. Gown, T.S. Barry, M.C. Cheang, A.K. Chan, D.A. Turbin, F.D. Hsu, R.B. West, and T.O. Nielsen. 2005. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18: 68-74.
138. Osaki, M., F. Takeshita, Y. Sugimoto, N. Kosaka, Y. Yamamoto, Y. Yoshioka, E. Kobayashi, T. Yamada, A. Kawai, T. Inoue, H. Ito, M. Oshimura, and T. Ochiya. 2011. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19: 1123-1130.
139. Ozaki, T., A. Hillmann, N. Lindner, S. Blasius, and W. Winkelmann. 1997. Chondrosarcoma of the pelvis. Clin Orthop Relat Res 337: 226-239.
140. Pardal, R., M.F. Clarke, and S.J. Morrison. 2003. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
141. Patrawala, L., T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool, and D.G. Tang. 2005. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219.
142. Pearce, D.J., D. Taussig, C. Simpson, K. Allen, A.Z. Rohatiner, T.A. Lister, and D. Bonnet. 2005. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23: 752-760.
143. Pendino, F., I. Tarkanyi, C. Dudognon, J. Hillion, M. Lanotte, J. Aradi, and E. Ségal-Bendirdjian. 2006. Telomeres and telomerase: Pharmacological targets for new anticancer strategies? Curr Cancer Drug Targets 6: 147-180.
144. Pevny, L.H., and S.K. Nicolis. 2010. Sox2 roles in neural stem cells. Int J Biochem Cell Biol 42: 421-424.
145. Plaisant, M., S. Giorgetti-Peraldi, M. Gabrielson, A. Loubat, C. Dani, and P. Peraldi. Inhibition of hedgehog signaling decreases proliferation and clonogenicity of human mesenchymal stem cells. PLoS One 6: e16798.
146. Provisor, A., L. Ettinger, J. Nachman, M.D. Krailo, J.T. Makley, and E.J. Yunis. 1997. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative andpostoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84.
147. Qiao, D., A.M. Zeeman, W. Deng, L.H. Looijenga, and H. Lin. 2002. Molecular characterization of hiwi, a human member of thepiwi gene family whose overexpression is correlated toseminomas. Oncogene 21: 3988-3999.
148. Que, J., X. Luo, R.J. Schwartz, and B.L. Hogan. 2009. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 136: 1899-1907.
149. Raimondi, L., R. Ciarapica, M. De Salvo, F. Verginelli, M. Gueguen, C. Martini, L. De Sio, G. Cortese, M. Locatelli, T.P. Dang, N. Carlesso, L. Miele, S. Stifani, I. Limon, F. Locatelli, and R. Rota. 2011. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumor cell growth in vitro and in vivo. Cell Death Differ 25.
150. Rasheed, Z.A., J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S.M. Hong, J.B. Koorstra, N.V. Rajeshkumar, X. He, M. Goggins, C. Iacobuzio-Donahue, D.M. Berman, D. Laheru, A. Jimeno, M. Hidalgo, A. Maitra, and W. Matsui. 2010. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102: 340-351.
151. Rasheed, Z.A., J. Kowalski, B.D. Smith, and W. Matsui. 2011. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29: 883-887.
152. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. 2001. Stem cells, cancer, and cancerstem cells. Nature 414: 105-111.
153. Reynolds, B.A., and S. Weiss. 1992. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707-1710.
154. Ricci-Vitiani, L., D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, and R. De Maria. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
155. Riggi, N., M.L. Suvà, C. De Vito, P. Provero, J.C. Stehle, K. Baumer, L. Cironi, M. Janiszewska, T. Petricevic, D. Suvà, S. Tercier, J.M. Joseph, L. Guillou, and I. Stamenkovic. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogrammingtoward Ewing sarcoma cancer stem cells. Genes Dev 24: 916-932.
156. Rot, S., H. Taubert, M. Bache, T. Greither, P. Wurl, A.W. Eckert, J. Schubert, D. Vordermark, and M. Kappler M. 2011. A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. BMC Cancer 11: 429.
157. Sadikovic, B., C. Graham, M. Ho, M. Zielenska, and G.R. Somers. 2011. Immunohistochemical expression and cluster analysis of mesenchymal and neural stem cell-associated proteins in pediatric soft tissue sarcomas. Pediatr Dev Pathol. 14: 259-272.
158. Sasaki, K., T. Hitora, O. Nakamura, R. Kono, and T. Yamamoto. 2011. The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res 31: 549-553.
159. Scott, S.M., H.M. Reiman, D.J. Pritchard, and D.M. Ilstrup. 1989. Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases. Cancer 64: 925-931.
160. Shi, S., and S. Gronthos. 2003. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 18: 696-704.
161. Shima, Y., T. Okamoto, T. Aoyama, K. Yasura, T. Ishibe, K. Nishijo, K.R. Shibata, Y. Kohno, K. Fukiage, S. Otsuka, D. Uejima, T. Nakayama, T. Nakamura, T. Kiyono, and J. Toguchida. 2007. In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. Biochem Biophys Res Commun 353: 60-66.
162. Shimono, Y., M. Zabala, R.W. Cho, N. Lobo, P. Dalerba, D. Qian, M. Diehn, H. Liu, S.P. Panula, E. Chiao, F.M. Dirbas, G. Somlo, R.A. Pera, K. Lao, and M.F. Clarke. 2009. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603.
163. Siclari, V.A., and L. Qin. 2010. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5: 78.
164. Singh, S.K., I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire, and P.B. Dirks. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
165. Singh, S.K., I.D. Clarke, T. Hide, and P.B. Dirks. 2004. Cancer stem cells in nervous system tumors. Oncogene. 23: 7267-7273.
166. Sladek, N.E. 2003. Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17: 7-23.
167. Song, B., Y. Wang, Y. Xi, K. Kudo, S. Bruheim, G.I. Botchkina, E. Gavin, Y. Wan, A. Formentini, M. Kornmann, O. Fodstad, and J. Ju. 2009. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065-4074.
168. Stratford, E.W., R. Castro, A. Wennerstrøm, R. Holm, M. Else, L. Silj, B. Bodil, and M. Ola. 2011. Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential Clinical Sarcoma Research 1: 8.
169. Subbiah, V., P. Anderson, A.J. Lazar, E. Burdett, K. Raymond, and J.A. Ludwig. 2009. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 10: 126-140.
170. Sulzbacher, I., P. Birner, C. Toma, N. Wick, and P.R. Mazal. 2007. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J Clin Pathol 60: 804-807.
171. Suvà, M.L., N. Riggi, J.C. Stehle, K. Baumer, S. Tercier, J.M. Joseph, D. Suvà, V. Clément, P. Provero, L. Cironi, M.C. Osterheld, L. Guillou, and I. Stamenkovic. 2009. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69: 1776-1781.
172. Ta, H.T., C.R. Dass, P.F. Choong, and D.E. Dunstan: Osteosarcoma treatment: stateof the art. Cancer Metastasis Rev 28: 247-263.
173. Tai, M.H., C.C. Chang, L.K. Olson, and J.E. Trosko. 2005. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502.
174. Takahashi, R., T. Fumitaka, T. Fujiwara, O. Makiko, and T. Ochiya. 2011. Review: Cancer Stem Cells in Breast Cancer. Cancers 3: 1311-1328.
175. Takebe, N., PJ. Harris, R.Q. Warren, and S.P. Ivy. 2011. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
176. Tang, Q.L., Y. Liang, X.B. Xie, J.Q. Yin, C.Y. Zou, Z.Q. Zhao, J.N. Shen, and J. Wang. 2011. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 30: 426-432.
177. Tang, Q.L., Z.Q. Zhao, J.C. Li, Y. Liang, J.Q. Yin, C.Y. Zou, X.B. Xie, Y.X. Zeng, J.N. Shen, T. Kang, and J. Wang. 2011. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 311: 113-121.
178. Taubert, H., T. Greither, D. Kaushal, P. Wurl, M. Bache, F. Bartel, A. Kehlen, C. Lautenschläger, L. Harris, K. Kraemer, A. Meye, M. Kappler, H. Schmidt, H.J. Holzhausen, and S. Hauptmann. 2007. Expression of the stem cell self-renewal geneHiwi and risk of tumor-related death in patients with soft tissuesarcoma. Oncogene 26: 1098-1100.
179. Taubert, H., P. Wurl, T. Greither, M. Kappler, M. Bache, F. Bartel, A. Kehlen, C. Lautenschlager, L.C. Harris, D. Kaushal, S. Fussel, A. Meye, A. Bohnke, H. Schmidt, H.J. Holzhausen, and S. Hauptmann. 2007. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 26: 7170-7174.
180. Terry, J., and T. Nielsen. 2010. Expression of CD133 in synovial sarcoma. Appl Immunohistochem Mol Morphol 18: 159-165.
181. Thorne, S.H., W. Liang, P. Sampath, T. Schmidt, R. Sikorski, A. Beilhack, and C.H. Contag. 2010. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther 18: 1698-1705.
182. Tirino, V., V. Desiderio, R. d'Aquino, F. De Francesco, G. Pirozzi, A. Graziano, U. Galderisi, C. Cavaliere, A. De Rosa, G. Papaccio, and A. Giordano. 2008. Detection and characterization of CD133+ cancer stem cells in human solid tumors. PLoS One 3: e3469.
183. Tirino, V., V. Desiderio, F. Paino, A. De Rosa, F. Papaccio, F. Fazioli, G. Pirozzi, and G. Papaccio. 2011. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25: 2022-2030.
184. Toguchida J. Sarcoma-initiating cells and tissue stem cells. pp. 65-71. In: H. Esumi, N. Takakura, K. Miyazono, M. Mori. [eds.]. 2009. Experimental Medicine. 27. Yodosha, Tokyo, Japan.
185. Toro, J.R., L.B. Travis, H.J. Wu, K. Zhu, C.D. Fletcher, and S.S. Devesa. 2006. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 119: 2922-2930.
186. Tostar, U., R. Toftgård, P.G. Zaphiropoulos, and T. Shimokawa. 2010. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer 1: 941-951.
187. Tsuchida, R., B. Das, H. Yeger, G. Koren, M. Shibuya, P.S. Thorner, S. Baruchel, and D. Malkin. 2008. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 27: 3923-3934.
188. Tsukahara, T., Y. Nabeta, S. Kawaguchi, H. Ikeda, Y. Sato, K. Shimozawa, K. Ida, H. Asanuma, Y. Hirohashi, T. Torigoe, H. Hiraga, S. Nagoya, T. Wada, T. Yamashita, and N. Sato. 2004. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64: 5442-5448.
189. Tsukahara, T., T. Torigoe, Y. Tamura, T. Wada, S. Kawaguchi, T. Tsuruma, K. Hirata, T. Yamashita, and N. Sato. 2008. Antigenic peptide vaccination: Provoking immune response and clinical benefit for cancer. Curr Immunol Rev 4: 235-241.
190. Tuan, R.S., G. Boland, and R. Tuli. 2003. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Research and Therapy 5: 32-45.
191. Veselska, R., M. Hermanova, T. Loja, P. Chlapek, I. Zambo, K. Vesely, K. Zitterbart, and J. Sterba. 2008. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer 8: 300.
192. Visvader, J.E. 2011. Cells of origin in cancer. Nature 469: 314-322.
193. Visvader, J.E., and G.J. Lindeman. 2008. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
194. Von Levetzow, C., X. Jiang, Y. Gwye, G. von Levetzow, L. Hung, A. Cooper, J.H. Hsu, and E.R. Lawlor. 2011. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One 6: e19305.
195. Wachtel, M., T. Runge, I. Leuschner, S. Stegmaier, E. Koscielniak, J. Treuner, B. Odermatt, S. Behnke, F.K. Niggli, and B.W. Schäfer. 2006. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24: 816-822.
196. Walter, D., S. Satheesha, P. Albrecht, B.C. Bornhauser, V. D'Alessandro, S.M. Oesch, H. Rehrauer, I. Leuschner, E. Koscielniak, C. Gengler, H. Moch, M. Bernasconi, F.K. Niggli, and B.W. Schäfer. 2011. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 6: e19506.
197. Wang, C., T. Maass, M. Krupp, F. Thieringer, S. Strand, M.A. Wörns, A.P. Barreiros, P.R. Galle, and A. Teufel. 2009. A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 50: 1122-1131.
198. Wang, L., P. Park, and C.Y. Lin. 2009. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 8.
199. Wang, L., P. Park, H. Zhang, F. La Marca, and C.Y. Lin. 2010. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128: 294-303.
200. Warner, J.K., J.C. Wang, K.J. Hope, L. Jin, and J.E. Dick. 2004. Concepts of human leukemic development. Oncogene 23: 7164-7177.
201. Watt, F.M., S. Estrach, and C.A. Ambler. 2008. Epidermal Notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol 20: 171-179.
202. Wei, H., M.Q. Zhao, W. Dong, Y. Yang, and J.S. Li. 2008. Expression of c-kit proteinand mutational status of the c-kit gene in osteosarcoma and theirclinicopathological significance. J Int Med Res 36: 1008-1014.
203. Weis, L.D. 1999. The success of limb-salvage surgery in the adolescentpatient with osteogenic sarcoma. Adolesc Med 10: 451-458.
204. Wesolowski, R., and G.T. Budd. 2010. Use of chemotherapy for patients with bone and soft-tissue sarcomas. Cleve Clin J Med 77 Suppl 1: S23-26.
205. Wilson, H., M. Huelsmeyer, R. Chun, K.M. Young, K. Friedrichs, and D.J. Argyle. 2008. Isolation and characterization of cancer stem cells from canine osteosarcoma. Vet J 175: 69-75.
206. Wick, M.R., G.P. Siegal, S.E. Mills, R.C. Thompson, D. Sawhney, and R.E. Fechner. 1987. Dedifferentiated chondrosarcoma of bone. An immunohistochemical and lectin-histochemical study. Virchows Arch A Pathol Anat Histopathol 411: 23-32.
207. Wu, C., and B.A. Alman. 2008. Side population cells in human cancers. Cancer Lett 268: 1-9.
208. Wu, C., Q. Wei, V. Utomo, P. Nadesan, H. Whetstone, R. Kandel, J.S. Wunder, and B.A. Alman. 2007. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 67: 8216-8222.
209. Xu, N., T. Papagiannakopoulos, G. Pan, J.A. Thomson, and K.S. Kosik. 2009. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 137: 647-658.
210. Yin, S., J. Li, C. Hu, X. Chen, M. Yao, M. Yan, G. Jiang, C. Ge, H. Xie, D. Wan, S. Yang, S. Zheng, and J. Gu. 2007. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
211. Young, A., J. Lyons, A.L. Miller, V.T. Phan, I.R. Alarcón, and F. McCormick. 2009. Ras signaling and therapies. Adv Cancer Res 102: 1-17.
212. Yuan, H., N. Corbi, C. Basilico, and L. Dailey. 1995. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev 9: 2635-2645.
213. Zamurovic, N., D. Cappellen, D. Rohner, and M. Susa. 2004. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279: 37704-37715.
214. Zeng, W., R. Wan, Y. Zheng, S.R. Singh, and Y. Wei. 2011. Hypoxia, stem cells and bone tumor. Cancer Lett 313: 129-136.
215. Zhang, P., Y. Yang, P.A. Zweidler-McKay, and D.P. Hughes. 2008. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 14: 2962-2969.
216. Zhou, S., J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi, and B.P Sorrentino. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034.